

## Greece

### Recent and planned developments in pharmaceutical policies 2017/2018

#### Special topic: patient involvement in pricing and reimbursement of medicines

##### CHANGES IN PRICING

- New price bulletin with general price revisions effective from February 2018
- Two subsequent price bulletins have been published with new active substances
- New managed entry agreement for patients with BRAFV600 positive metastatic melanoma
- VAT remains the same (6% and 13% in special cases)
- Abolition of the Pricing Committee and transferring the authority directly to the Minister of Health after respective proposal from the National Drug Organization (EOF)

##### CHANGES IN REIMBURSEMENT

New legislation in place for the introduction of Health Technology Assessment for pharmaceuticals and reformation of the Negotiation Committee for Pharmaceuticals (Law 4512/2018-Official Gazette 5A/17.01.2018):

- Establishment for HTA Committee for Pharmaceuticals (articles 247-253) to be used as a transitory step up to the establishment of the HTA Organization
- Negotiation Committee for Medicines (articles 254-256) mainly refers to the establishment of the Negotiation Committee in the Ministry of Health giving the authority to negotiate agreements for both the reimbursement fund (EOPYY) and public hospitals. A Negotiation Committee for medical devices and healthcare services will continue to work in EOPYY (art.255 L. 4512/2018)
- All new active substances have to be evaluated by the HTA Committee and be referred to the Negotiation Committee for the estimation of the budget impact.
- However it exist in parallel that a new active substances will only be included in the List of Reimbursable Medicinal Products if they are reimbursed in two thirds (2/3) of the EU Member States in which they are marketed, provided that the Members States in which they are marketed are at least nine (9), and at least half of the Member States in which the medicine is reimbursed are included in the following list of Members States applying Health Technology Assessment mechanisms in respect of medicinal products for human use: Austria, Belgium, Great Britain, France, Spain, Netherlands, Portugal, Sweden and Finland.

##### OTHERS CHANGES

- New electronic system for supporting prior authorization procedure for pharmaceuticals
- New therapeutic protocols for: dyslipidemia, hypertension, osteoporosis, acute infections (acute bronchitis, community pneumonia) will be uploaded in the e-prescription system.
- New registry for Chronic Myelogenic Leukaemia is live together with the already existing of Hepatitis C.
- Registries under development for Multiple Sclerosis and Immunotherapies
- New web application for Marketing Authorization Holders/local distributors providing access to reimbursement data.

#### SPECIAL TOPIC: Patient Involvement in Pricing and Reimbursement of Medicines

